Non-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Children >1 year of age, Adolescents and Adults with X-Linked Hypophosphataemia (XLH PASS)

First published 06/11/2019

Last updated 19/05/2025

EU PAS number:

EUPAS32190

Study

Ongoing

Documents

Study protocol

Initial protocol

XLH Registry Protocol Amendment 2_Final_15Feb2019.pdf

English (878.72 KB - PDF)View document

Updated protocol

XLH Registry Protocol Amendment 3 with embedded PASS_27Oct2021_clean.pdf

First published: 15/05/2024

English (1.34 MB - PDF)View document

Study results

Study report

Other information

Study, other information

PASS Annual Progress Report 2019

English (133.59 KB - PDF)View document

PASS Annual Progress Report 2020

English (1.38 MB - PDF)View document

PASS Interim Study Report 4Oct2021

English (1.48 MB - PDF)View document

PASS Annual Progress Report 2022

English (198.31 KB - PDF)View document

PASS Annual Progress Report 2023

English (254.01 KB - PDF)View document

PASS Annual Progress Report 2024.pdf

English (283.98 KB - PDF)View document

PASS Annual Progress Report 2025.pdf

English (651.2 KB - PDF)View document

ENCePP Seal

ENCePP Seal documents

Secondary tabs